Overview

The Young Adult and Pediatric Bipolar Study

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.

Phase:

Phase 4

Details

Lead Sponsor:

Validus Pharmaceuticals

Treatments:

Carbamazepine